

Tablica 10. Prvih 30 lijekova prema financijskoj potrošnji izraženo u eurima u 2025. godini, bolnička potrošnja

RBR	ATK	INN	UKUPNI IZNOS (EUR)
1	L01FF02	pembrolizumab	110.815.787
2	L01FC01	daratumumab	30.922.946
3	L02BB04	enzalutamid	26.498.379
4	L01FG01	bevacizumab	22.728.370
5	L01FY01	pertuzumab i trastuzumab	22.277.048
6	L04AG08	okrelizumab	21.272.030
7	L01FF01	nivolumab	20.888.215
8	L01FF05	atezolizumab	18.674.260
9	L01EL01	ibrutinib	16.447.374
10	B05AA01	albumin, ljudski	16.115.549
11	L04AX04	lenalidomid	15.854.567
12	J06BA02	imunoglobulini, humani, za i.v. primjenu	15.759.247
13	L01EB04	osimertinib	12.395.240
14	L01EF02	ribociklib	12.376.670
15	M09AX10	risdiplam	11.854.622
16	L01FF03	durvalumab	11.648.160
17	R07AX32	ivakaftor, tezakaftor i eleksakaftor	11.527.208
18	L04AB02	infliksimab	11.347.136
19	L03AA13	pegfilgrastim	11.044.486
20	L02BB05	apalutamid	10.437.853
21	L01FX14	polatuzumab vedotin	10.340.130
22	L01XX52	venetoklaks	10.041.015
23	L01EL02	akalabrutinib	9.810.076
24	L01XK01	olaparib	9.475.609
25	L01FX04	ipilimumab	9.272.680
26	L01EF01	palbociklib	9.202.785
27	L01FA01	rituksimab	8.579.788
28	L04AA43	ravulizumab	8.192.951
29	L01EF03	abemaciclib	8.030.791
30	L01FD04	trastuzumab derukstekan	7.690.343